

INVESTMENT
RESEARCH CENTER

Provided by Fairfax County Public Library

Sunday, Jan. 10, 2010

Contact

End Session

[Home](#) | [Stocks](#) | [Funds](#) | [ETFs](#) | [Industries](#) | [Portfolio X-Ray](#) | [Help & Education](#)

Enter a Ticker or Name

Print

Snapshot

Quote

Analyst Research

Morningstar Rating

Options

Data Interpreter

Valuation Ratios

Financial Statements

Key Ratios

Charts

Dividends & Returns

Company Filings **new**

Insider Trading

Formatted Report

Print

C.R. Bard, Inc. BCR**Analyst Report**[Analyst Report Archive](#)[Top Rated Stocks in Sector](#)by [Meera Venu](#)**Thesis** 12-15-2009

Over the past century, C.R. Bard has transformed itself from a distributor of urological devices into a diversified medical device firm and captured market-leading positions in several niches. While we worry about low switching costs in the industry, the firm's differentiated products and high returns on invested capital create a narrow economic moat.

C.R. Bard has invested in high-growth areas in the vascular market and distinguishes its products through clinically proven efficacy. The largest portion of this segment consists of devices for endovascular procedures, a \$2 billion market growing in the double digits. C.R. Bard's most unique products include the Flair stent graft, which has clinically demonstrated that it can improve graft function, and LifeStent line, which touts unique indications in leg and knee arteries, low fracture rates, and one of the longest stents on the market. The firm also has targeted the high-growth atrial fibrillation market with diagnostic equipment and catheters. Already approved in Europe, C.R. Bard's HD ablation catheter is in the midst of trials in the United States to prove efficacy versus drug therapy. While we think these devices will propel this segment's growth, their advantages over competitors will not last forever. For example, Cook Medical seeks to launch a drug-eluting stent in the U.S. with a leg artery indication. Physicians can also use rival devices off-label. Thus, C.R. Bard will need to continue to prove quality and focus on better patient outcomes to woo customers and deliver innovative products to outpace rivals.

We think cost-effectiveness is the main selling point of the firm's urology product line. C.R. Bard pioneered the Foley catheter, which has become the leading device for bladder drainage and the firm's largest-selling product. Now we think this segment's growth will rest with infection-control catheters and stabilization devices, which appeal to hospitals looking to decrease complication costs (such as urinary tract infections for which Medicare no longer reimburses), reduce injuries, and improve quality of care. The firm's oncology segment also offers high-tech catheters and ports for chemotherapy. Its products allow nurses to conveniently place catheters at bedsides, flush devices less often, and use fewer catheters. Despite these attributes, heavy competition and low switching costs pose a risk to C.R. Bard's position in both segments. Urology products are also largely sold through distributors, so inventory adds variability onto sales.

Overall though, we think C.R. Bard has the tools to battle these challenges and sustain high returns on capital.

Valuation

We value C.R. Bard at \$84 per share. We think the firm can grow at a compound annual rate of 6% until 2014, after bringing in about \$2.5 billion in sales in 2009. We believe revenue can near \$3.5 billion by that year. We think the

Morningstar Rating

★★★

Stock PriceAs of 12-15-2009
\$85.02**Fair Value Estimate**

\$84.00

Consider Buying

\$58.80

Consider Selling

\$117.60

Fair Value Uncertainty

Medium

Economic Moat

Narrow

Stewardship Grade **C****Bulls Say**

- C.R. Bard's line of infection-control products might appeal to hospitals that need to improve clinical outcomes or cut costs of complications. Higher adoption could boost urology segment growth.
- Some of C.R. Bard's segments benefit from demographic trends. For example, increasing obesity trends can fuel the market for treatment of peripheral vascular disease.
- Of the firm's sales, 90% come from consumables, which provide an ongoing revenue stream and high margins. This mix helps the firm weather equipment sales declines when capital spending is low.

Bears Say

- C.R. Bard's more capable devices command a premium to their basic alternatives. Physicians and hospitals many not see a need for this added functionality, especially in tougher economic times.
- Physicians may not feel the need to change their procedures or train nurses on new devices, which could

oncology segments will largely drive this growth, with a 10% annual rate thanks to greater adoption of specialty access products. We expect competition to weigh on stent market share in the vascular business, but we think electrophysiology products will grow robustly. We predict operating margins will increase to 29% in 2009 because of restructuring. In the long run, though, we think margins will fall to about 27% by 2014, primarily as competitive forces in the vascular segment constrict volume flowing through C.R. Bard's manufacturing operations. We discount our assumptions at a 10% cost of capital.

Risk

The firm faces the risk of product recalls if defects are found in devices. Switching costs remain low in surgical devices, so if competitors come out with better technology, surgeons can easily switch suppliers. About one third of the firm's sales come from international markets. Swings in foreign exchange rates could hurt growth rates. Sales of the firm's products also depend on surgical procedures, which can slow down in tough economic times.

slow adoption.

- Product delays can hurt market share and growth. C.R. Bard has recently experienced delays with its surgical sling business, which could push customers elsewhere.

Close Competitors	TTM Sales \$Mil	Market Cap \$Mil
C.R. Bard, Inc.	2,492	7,772
* <u>Boston Scientific, Inc.</u>	8,111	13,594
* <u>Johnson & Johnson</u>	60,528	177,162
* <u>Baxter International Inc.</u>	12,223	35,671
* <u>Covidien, Ltd.</u>	10,677	24,466

* Morningstar Analyst Report Available

Data as of 09-30-09

Strategy

C.R. Bard aims to market products in niches where it can attain or maintain a market-leading share. In the past, the firm has divested itself of product lines that do not meet these goals. C.R. Bard tries to develop products for markets where physicians, not administrators, make purchasing decisions based on product quality and outcome.

Management & Stewardship

We think C.R. Bard has fair corporate governance and give it a C Stewardship Grade. Chairman and CEO Timothy Ring has held his position since 2003. He brings a wealth of experience to the firm, with 16 years at the firm and previous managerial positions at Abbott Laboratories ABT. Ring holds a 1% stake in the firm, which should help align his interests with shareholders. We like that the firm employs majority voting rules for uncontested director elections, which can provide shareholders with a form of veto power. We also approve of the high degree of variable awards in executives' and directors' compensation packages. These awards help align pay with performance. However, we think the CEO's total compensation of \$9 million in 2008 looks high in comparison with peers; many bring in higher sales and profits with lower executive compensation rates than C.R. Bard. We also would like to see more disclosure on performance goals. We would rather the firm split the positions of chairman and CEO in order to ensure board independence. Also, we wish that the firm would elect board members annually. The staggered board structure and the firm's golden parachute payments serve as antitakeover provisions.

Profile

C.R. Bard develops and markets medical devices worldwide. Its products consist mostly of disposables and implantable devices for vascular, urology, and oncology procedures. The remainder of its sales comes from its surgical specialties line.

The firm derives about 80% of its revenue from products that hold market-leading positions.

Growth

We forecast a five-year compound annual growth rate of 6% until 2014. We predict oncology will drive this rate with 10% annual growth and vascular to average 6% growth because of greater competition. The firm's largest segment, urology, should grow modestly.

Profitability

We predict a 29% operating margin in 2009. We think the firm's margin will settle down to 27% by 2014, as cost savings from general and administrative costs are offset by potential pricing pressure in the vascular segment and higher research spending.

Financial Health

C.R. Bard remains in strong financial health. As of September 2009, the firm held \$482 million in net cash. The firm can pay off its \$150 million notes by its 2026 maturity. In the interim, the firm can deploy excess cash for repurchases and dividends.

Authors can be reached at [analyst feedback](#).

Morningstar's editorial policies prohibit analysts from owning stocks they cover. Find out more about Morningstar's editorial policies [here](#).

Morningstar Ratings and Morningstar Risk are updated daily.

[Show Data Definitions](#) | [Ticker Lookup](#)